MA33825B1 - Analogue du peptide d'oxyntomoduline - Google Patents
Analogue du peptide d'oxyntomodulineInfo
- Publication number
- MA33825B1 MA33825B1 MA34968A MA34968A MA33825B1 MA 33825 B1 MA33825 B1 MA 33825B1 MA 34968 A MA34968 A MA 34968A MA 34968 A MA34968 A MA 34968A MA 33825 B1 MA33825 B1 MA 33825B1
- Authority
- MA
- Morocco
- Prior art keywords
- oxytomodline
- polypeptide compounds
- polypeptide
- compounds
- oxyntomodulin
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- PXZWGQLGAKCNKD-DPNMSELWSA-N molport-023-276-326 Chemical class C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 PXZWGQLGAKCNKD-DPNMSELWSA-N 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Obesity (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Child & Adolescent Psychology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28888809P | 2009-12-22 | 2009-12-22 | |
| US35257610P | 2010-06-08 | 2010-06-08 | |
| PCT/US2010/060390 WO2011087672A1 (en) | 2009-12-22 | 2010-12-15 | Oxyntomodulin peptide analogue |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA33825B1 true MA33825B1 (fr) | 2012-12-03 |
Family
ID=43587001
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA34968A MA33825B1 (fr) | 2009-12-22 | 2012-06-14 | Analogue du peptide d'oxyntomoduline |
Country Status (34)
| Country | Link |
|---|---|
| US (1) | US8367607B2 (https=) |
| EP (1) | EP2515928B1 (https=) |
| JP (1) | JP5717759B2 (https=) |
| KR (1) | KR101399671B1 (https=) |
| CN (1) | CN102740873B (https=) |
| AR (1) | AR079345A1 (https=) |
| AU (1) | AU2010341651B2 (https=) |
| BR (1) | BR112012017348B1 (https=) |
| CA (1) | CA2784671C (https=) |
| CL (1) | CL2012001686A1 (https=) |
| CO (1) | CO6551738A2 (https=) |
| CR (1) | CR20120338A (https=) |
| DK (1) | DK2515928T3 (https=) |
| DO (1) | DOP2012000176A (https=) |
| EA (1) | EA022820B1 (https=) |
| ES (1) | ES2486675T3 (https=) |
| HN (1) | HN2012001321A (https=) |
| HR (1) | HRP20140616T1 (https=) |
| IL (1) | IL220161B (https=) |
| JO (1) | JO2976B1 (https=) |
| MA (1) | MA33825B1 (https=) |
| MX (1) | MX2012007438A (https=) |
| MY (1) | MY160773A (https=) |
| NZ (1) | NZ600731A (https=) |
| PE (1) | PE20121393A1 (https=) |
| PH (1) | PH12012501263B1 (https=) |
| PL (1) | PL2515928T3 (https=) |
| PT (1) | PT2515928E (https=) |
| RS (1) | RS53505B1 (https=) |
| SG (1) | SG181430A1 (https=) |
| SI (1) | SI2515928T1 (https=) |
| TN (1) | TN2012000302A1 (https=) |
| TW (1) | TWI423812B (https=) |
| WO (1) | WO2011087672A1 (https=) |
Families Citing this family (82)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7731947B2 (en) | 2003-11-17 | 2010-06-08 | Intarcia Therapeutics, Inc. | Composition and dosage form comprising an interferon particle formulation and suspending vehicle |
| WO2006083761A2 (en) | 2005-02-03 | 2006-08-10 | Alza Corporation | Solvent/polymer solutions as suspension vehicles |
| US11246913B2 (en) | 2005-02-03 | 2022-02-15 | Intarcia Therapeutics, Inc. | Suspension formulation comprising an insulinotropic peptide |
| CA2913805A1 (en) | 2005-11-07 | 2007-05-18 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting physiological solubility and stability |
| US9249407B2 (en) | 2006-02-03 | 2016-02-02 | Opko Biologics Ltd. | Long-acting coagulation factors and methods of producing same |
| US8946155B2 (en) | 2006-02-03 | 2015-02-03 | Opko Biologics Ltd. | Long-acting polypeptides and methods of producing and administering same |
| US10351615B2 (en) | 2006-02-03 | 2019-07-16 | Opko Biologics Ltd. | Methods of treatment with long-acting growth hormone |
| US9458444B2 (en) | 2006-02-03 | 2016-10-04 | Opko Biologics Ltd. | Long-acting coagulation factors and methods of producing same |
| US20140113860A1 (en) | 2006-02-03 | 2014-04-24 | Prolor Biotech Ltd. | Long-acting polypeptides and methods of producing and administering same |
| US20150038413A1 (en) | 2006-02-03 | 2015-02-05 | Opko Biologics Ltd. | Long-acting polypeptides and methods of producing and administering same |
| US10221228B2 (en) | 2006-02-03 | 2019-03-05 | Opko Biologics Ltd. | Long-acting polypeptides and methods of producing and administering same |
| US8048849B2 (en) | 2006-02-03 | 2011-11-01 | Modigene, Inc. | Long-acting polypeptides and methods of producing same |
| KR101106510B1 (ko) | 2006-05-30 | 2012-01-20 | 인타르시아 세라퓨틱스 인코포레이티드 | 투피스, 내부채널 삼투압 전달 시스템 유동 조절기 |
| EP2359808B1 (en) | 2006-08-09 | 2013-05-22 | Intarcia Therapeutics, Inc | Osmotic delivery systems and piston assemblies |
| CA2677932A1 (en) | 2007-02-15 | 2008-08-21 | Indiana University Research And Technology Corporation | Glucagon/glp-1 receptor co-agonists |
| WO2008133908A2 (en) | 2007-04-23 | 2008-11-06 | Intarcia Therapeutics, Inc. | Suspension formulations of insulinotropic peptides and uses thereof |
| ES2509883T3 (es) | 2007-10-30 | 2014-10-20 | Indiana University Research And Technology Corporation | Antagonistas de glucagón |
| MX2010004298A (es) | 2007-10-30 | 2010-05-03 | Univ Indiana Res & Tech Corp | Compuestos que exhiben actividad antagonista de glucagon y agonista de glp-1. |
| CA2726861C (en) | 2008-02-13 | 2014-05-27 | Intarcia Therapeutics, Inc. | Devices, formulations, and methods for delivery of multiple beneficial agents |
| CN102105159B (zh) | 2008-06-17 | 2015-07-08 | 印第安纳大学研究及科技有限公司 | 基于gip的混合激动剂用于治疗代谢紊乱和肥胖症 |
| PE20120332A1 (es) | 2008-12-19 | 2012-04-14 | Univ Indiana Res & Tech Corp | Profarmacos de peptido de la superfamilia de glucagon basado en amida |
| EP2443146B1 (en) | 2009-06-16 | 2016-10-05 | Indiana University Research And Technology Corporation | Gip receptor-active glucagon compounds |
| US9663778B2 (en) | 2009-07-09 | 2017-05-30 | OPKO Biologies Ltd. | Long-acting coagulation factors and methods of producing same |
| US12203113B2 (en) | 2009-07-09 | 2025-01-21 | Opko Biologics Ltd. | Long-acting coagulation factors and methods of producing same |
| RU2547990C2 (ru) | 2009-09-28 | 2015-04-10 | Интарсия Терапьютикс, Инк. | Быстрое достижение и/или прекращение существенной стабильной доставки лекарственного средства |
| KR20120123443A (ko) | 2010-01-27 | 2012-11-08 | 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 | 대사 장애 및 비만 치료용 글루카곤 길항제-ｇｉｐ 항진제 콘쥬게이트 |
| MX2012013001A (es) | 2010-05-13 | 2013-02-26 | Univ Indiana Res & Tech Corp | Peptidos de la superfamilia de glucagon que presentan actividad del receptor nuclear de hormonas. |
| JP6050746B2 (ja) | 2010-05-13 | 2016-12-21 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションIndiana University Research And Technology Corporation | Ｇタンパク質共役受容体活性を示すグルカゴンスーパーファミリーのペプチド |
| US8507428B2 (en) | 2010-12-22 | 2013-08-13 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting GIP receptor activity |
| US20120208755A1 (en) | 2011-02-16 | 2012-08-16 | Intarcia Therapeutics, Inc. | Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers |
| US10166295B2 (en) | 2011-06-02 | 2019-01-01 | Opko Biologics Ltd. | Pegylated OXM variants |
| UA126465C2 (uk) | 2011-06-10 | 2022-10-12 | Ханмі Сайенс Ко., Лтд. | Пептид, що має активність оксинтомодуліну, та фармацевтична композиція для лікування ожиріння, яка його містить |
| RU2607365C2 (ru) | 2011-06-17 | 2017-01-10 | Ханми Сайенс Ко., Лтд. | Конъюгат, содержащий оксинтомодулин и фрагмент иммуноглобулина, и его применение |
| KR20140043793A (ko) | 2011-06-22 | 2014-04-10 | 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 | 글루카곤/glp-1 수용체 공동-작용물질 |
| RS56173B1 (sr) | 2011-06-22 | 2017-11-30 | Univ Indiana Res & Tech Corp | Koagonisti receptora za glukagon/glp-1 receptora |
| JP6324315B2 (ja) | 2011-11-17 | 2018-05-16 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ | グルココルチコイド受容体の活性を示すグルカゴンスーパーファミリーのペプチド |
| HK1207564A1 (en) | 2012-04-19 | 2016-02-05 | Opko Biologics Ltd | Long-acting oxyntomodulin variants and methods of producing same |
| EA201492269A1 (ru) | 2012-06-04 | 2016-02-29 | Опко Байолоджикс Лтд. | Пегилированные варианты oxm |
| CN104583232B (zh) | 2012-06-21 | 2018-04-13 | 印第安纳大学研究及科技有限公司 | 展现gip受体活性的胰高血糖素类似物 |
| KR101968344B1 (ko) * | 2012-07-25 | 2019-04-12 | 한미약품 주식회사 | 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물 |
| AR092873A1 (es) | 2012-09-26 | 2015-05-06 | Cadila Healthcare Ltd | Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon |
| UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
| KR101993393B1 (ko) * | 2012-11-06 | 2019-10-01 | 한미약품 주식회사 | 옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물 |
| WO2014073842A1 (en) | 2012-11-06 | 2014-05-15 | Hanmi Pharm. Co., Ltd. | Liquid formulation of protein conjugate comprising the oxyntomodulin and an immunoglobulin fragment |
| HUE055348T2 (hu) | 2012-11-20 | 2021-11-29 | Opko Biologics Ltd | Eljárás polipeptidek hidrodinamikus térfogatának növelésére gonadotropin karboxil-terminális peptidekhez való kapcsolással |
| AU2013366692B2 (en) | 2012-12-21 | 2017-11-23 | Sanofi | Dual GLP1/GIP or trigonal GLP1/GIP/Glucagon agonists |
| US20150158926A1 (en) | 2013-10-21 | 2015-06-11 | Opko Biologics, Ltd. | Long-acting polypeptides and methods of producing and administering same |
| WO2015086733A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Dual glp-1/glucagon receptor agonists |
| EP3080152A1 (en) | 2013-12-13 | 2016-10-19 | Sanofi | Non-acylated exendin-4 peptide analogues |
| WO2015086728A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Exendin-4 peptide analogues as dual glp-1/gip receptor agonists |
| EP3080154B1 (en) | 2013-12-13 | 2018-02-07 | Sanofi | Dual glp-1/gip receptor agonists |
| TW201625670A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑 |
| TW201625669A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑 |
| TW201625668A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物 |
| US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
| TWI802396B (zh) | 2014-09-16 | 2023-05-11 | 南韓商韓美藥品股份有限公司 | 長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途 |
| US9889085B1 (en) | 2014-09-30 | 2018-02-13 | Intarcia Therapeutics, Inc. | Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c |
| EP3230309B1 (en) | 2014-12-10 | 2023-03-29 | OPKO Biologics Ltd. | Methods of producing long acting ctp-modified growth hormone polypeptides |
| KR102418477B1 (ko) | 2014-12-30 | 2022-07-08 | 한미약품 주식회사 | 글루카곤 유도체 |
| RU2730996C2 (ru) | 2015-06-03 | 2020-08-26 | Интарсия Терапьютикс, Инк. | Системы установки и извлечения имплантата |
| AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
| WO2016198628A1 (en) | 2015-06-12 | 2016-12-15 | Sanofi | Non-acylated exendin-4 derivatives as dual glp-1/glucagon receptor agonists |
| WO2016198624A1 (en) | 2015-06-12 | 2016-12-15 | Sanofi | Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists |
| PL3310347T3 (pl) | 2015-06-19 | 2021-12-27 | Opko Biologics Ltd. | Długo działające czynniki krzepnięcia i sposoby wytwarzania |
| TWI700291B (zh) | 2015-06-22 | 2020-08-01 | 美國禮來大藥廠 | 升糖素及glp-1共激動劑化合物 |
| TW201706291A (zh) | 2015-07-10 | 2017-02-16 | 賽諾菲公司 | 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物 |
| TWI622596B (zh) | 2015-10-26 | 2018-05-01 | 美國禮來大藥廠 | 升糖素受體促效劑 |
| KR102574993B1 (ko) | 2016-05-16 | 2023-09-06 | 인타르시아 세라퓨틱스 인코포레이티드 | 글루카곤-수용체 선택적 폴리펩티드 및 이들의 이용 방법 |
| USD860451S1 (en) | 2016-06-02 | 2019-09-17 | Intarcia Therapeutics, Inc. | Implant removal tool |
| USD840030S1 (en) | 2016-06-02 | 2019-02-05 | Intarcia Therapeutics, Inc. | Implant placement guide |
| EP3468610A1 (en) | 2016-06-09 | 2019-04-17 | OPKO Biologics Ltd. | Long-acting oxyntomodulin formulation and methods of producing and administering same |
| MY206271A (en) | 2016-07-11 | 2024-12-06 | Opko Biologics Ltd | Long-acting coagulation factor vii and methods of producing same |
| TW201832783A (zh) | 2016-12-02 | 2018-09-16 | 法商賽諾菲公司 | 包含ｇｌｐ－１／胰高血糖素雙重激動劑、連接子和透明質酸的接合物 |
| JP7286542B2 (ja) | 2017-01-03 | 2023-06-05 | インターシア セラピューティクス，インコーポレイティド | Ｇｌｐ－１受容体アゴニストの持続的投与及び薬物の同時投与を含む方法 |
| CN108299553B (zh) * | 2017-01-13 | 2021-07-16 | 博瑞生物医药（苏州）股份有限公司 | 胃泌酸调节素修饰物 |
| KR20200135618A (ko) * | 2019-05-23 | 2020-12-03 | ㈜ 디앤디파마텍 | 폴리펩티드를 포함하는 비알코올성 지방간 질환의 예방 또는 치료용 약학 조성물 |
| KR101990075B1 (ko) * | 2018-07-19 | 2019-06-18 | ㈜ 디앤디파마텍 | 폴리펩티드를 포함하는 비만 예방 또는 치료용 약학 조성물 |
| CN121591873A (zh) * | 2018-07-19 | 2026-03-03 | D&D制药技术股份有限公司 | 包括多肽的药物组合物 |
| US12441776B2 (en) * | 2018-11-30 | 2025-10-14 | Eirgen Pharma Ltd. | Oxyntomodulin peptide analog formulations |
| WO2025169190A2 (en) | 2024-02-06 | 2025-08-14 | Opko Biologics Ltd. | Modified oxyntomodulin and methods of use thereof |
| WO2026075985A1 (en) | 2024-10-01 | 2026-04-09 | Neolaia Inc. | Quinoline- and quinazoline-carboxamide derivatives as cd38 inhibitors |
| WO2026075971A1 (en) | 2024-10-01 | 2026-04-09 | Neolaia Inc. | Combination therapy for treatment of metabolic disorders and inflamation related disorders using incretin compounds and cd38 inhibitors |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5445090A (en) | 1991-07-25 | 1995-08-29 | Mim Industries, Inc. | Interchangeable clamp for use in a sewing machine |
| US5446090A (en) | 1993-11-12 | 1995-08-29 | Shearwater Polymers, Inc. | Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules |
| US5858975A (en) * | 1994-11-07 | 1999-01-12 | Kyowa Hakko Kogyo Co., Ltd. | Oxyntomodulin peptide having cardiotonic activity and insulin release-bromating activity |
| US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
| US6214966B1 (en) | 1996-09-26 | 2001-04-10 | Shearwater Corporation | Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution |
| US6448369B1 (en) | 1997-11-06 | 2002-09-10 | Shearwater Corporation | Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation |
| JP4078032B2 (ja) | 1998-03-12 | 2008-04-23 | ネクター セラピューティックス エイエル，コーポレイション | 近位の反応性基を持つポリ（エチレングリコール）誘導体 |
| CA2394980C (en) | 1999-12-22 | 2008-05-13 | Shearwater Corporation | Sterically hindered derivatives of water soluble polymers |
| US6413507B1 (en) | 1999-12-23 | 2002-07-02 | Shearwater Corporation | Hydrolytically degradable carbamate derivatives of poly (ethylene glycol) |
| US6436386B1 (en) | 2000-11-14 | 2002-08-20 | Shearwater Corporation | Hydroxyapatite-targeting poly (ethylene glycol) and related polymers |
| GB0121709D0 (en) | 2001-09-07 | 2001-10-31 | Imp College Innovations Ltd | Food inhibition agent |
| GB0300571D0 (en) | 2003-01-10 | 2003-02-12 | Imp College Innovations Ltd | Modification of feeding behaviour |
| JP2006520818A (ja) | 2003-03-19 | 2006-09-14 | イーライ リリー アンド カンパニー | ポリエチレングリコール結合ｇｌｐ−１化合物 |
| CA2608311C (en) | 2005-05-13 | 2012-11-27 | Eli Lilly And Company | Glp-1 pegylated compounds |
| GB0511986D0 (en) * | 2005-06-13 | 2005-07-20 | Imp College Innovations Ltd | Novel compounds and their effects on feeding behaviour |
| ATE553124T1 (de) | 2005-06-13 | 2012-04-15 | Imp Innovations Ltd | Oxyntomodulinanaloga und ihre wirkungen auf das fressverhalten |
| CA2913805A1 (en) | 2005-11-07 | 2007-05-18 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting physiological solubility and stability |
| CA2638800A1 (en) * | 2006-02-22 | 2007-09-07 | Merck & Co., Inc. | Oxyntomodulin derivatives |
| TWI428346B (zh) | 2006-12-13 | 2014-03-01 | Imp Innovations Ltd | 新穎化合物及其等對進食行為影響 |
| CA2677932A1 (en) | 2007-02-15 | 2008-08-21 | Indiana University Research And Technology Corporation | Glucagon/glp-1 receptor co-agonists |
| EP2158214B1 (en) | 2007-06-15 | 2011-08-17 | Zealand Pharma A/S | Glucagon analogues |
| WO2009030771A1 (en) * | 2007-09-05 | 2009-03-12 | Novo Nordisk A/S | Peptides derivatized with a-b-c-d- and their therapeutical use |
| WO2010096052A1 (en) | 2009-02-19 | 2010-08-26 | Merck Sharp & Dohme Corp. | Oxyntomodulin analogs |
| AR079344A1 (es) * | 2009-12-22 | 2012-01-18 | Lilly Co Eli | Analogo peptidico de oxintomodulina, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para tratar diabetes no insulinodependiente y/u obesidad |
-
2010
- 2010-12-09 JO JO2010438A patent/JO2976B1/en active
- 2010-12-09 AR ARP100104555A patent/AR079345A1/es active IP Right Grant
- 2010-12-10 TW TW099143356A patent/TWI423812B/zh active
- 2010-12-15 WO PCT/US2010/060390 patent/WO2011087672A1/en not_active Ceased
- 2010-12-15 SG SG2012036844A patent/SG181430A1/en unknown
- 2010-12-15 RS RSP20140437 patent/RS53505B1/sr unknown
- 2010-12-15 NZ NZ600731A patent/NZ600731A/en unknown
- 2010-12-15 MY MYPI2012002859A patent/MY160773A/en unknown
- 2010-12-15 EP EP10801033.1A patent/EP2515928B1/en active Active
- 2010-12-15 ES ES10801033.1T patent/ES2486675T3/es active Active
- 2010-12-15 AU AU2010341651A patent/AU2010341651B2/en active Active
- 2010-12-15 JP JP2012546035A patent/JP5717759B2/ja active Active
- 2010-12-15 BR BR112012017348A patent/BR112012017348B1/pt active IP Right Grant
- 2010-12-15 HR HRP20140616AT patent/HRP20140616T1/hr unknown
- 2010-12-15 DK DK10801033.1T patent/DK2515928T3/da active
- 2010-12-15 SI SI201030672T patent/SI2515928T1/sl unknown
- 2010-12-15 PT PT108010331T patent/PT2515928E/pt unknown
- 2010-12-15 US US12/968,382 patent/US8367607B2/en active Active
- 2010-12-15 PL PL10801033T patent/PL2515928T3/pl unknown
- 2010-12-15 CN CN201080058417.3A patent/CN102740873B/zh active Active
- 2010-12-15 EA EA201290549A patent/EA022820B1/ru not_active IP Right Cessation
- 2010-12-15 PE PE2012000854A patent/PE20121393A1/es active IP Right Grant
- 2010-12-15 CA CA2784671A patent/CA2784671C/en active Active
- 2010-12-15 KR KR1020127016089A patent/KR101399671B1/ko active Active
- 2010-12-15 MX MX2012007438A patent/MX2012007438A/es active IP Right Grant
- 2010-12-15 PH PH1/2012/501263A patent/PH12012501263B1/en unknown
-
2012
- 2012-06-04 IL IL220161A patent/IL220161B/en active IP Right Grant
- 2012-06-14 TN TNP2012000302A patent/TN2012000302A1/en unknown
- 2012-06-14 MA MA34968A patent/MA33825B1/fr unknown
- 2012-06-20 DO DO2012000176A patent/DOP2012000176A/es unknown
- 2012-06-21 HN HN2012001321A patent/HN2012001321A/es unknown
- 2012-06-21 CO CO12104391A patent/CO6551738A2/es active IP Right Grant
- 2012-06-21 CL CL2012001686A patent/CL2012001686A1/es unknown
- 2012-06-22 CR CR20120338A patent/CR20120338A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA33825B1 (fr) | Analogue du peptide d'oxyntomoduline | |
| MA33826B1 (fr) | Analogue du peptide d'oxyntomoduline | |
| FR21C1004I1 (https=) | ||
| MX356584B (es) | Analogos de tiazolidindiona para el tratamiento de enfermedad mediada por inflamacion metabolica. | |
| MX2009004532A (es) | Composiciones y metodos para unir esfingosina-1-fosfato. | |
| UA107600C2 (uk) | АНТИТІЛО ПРОТИ N3pGlu БЕТА-АМІЛОЇДНОГО ПЕПТИДУ ТА ЙОГО ЗАСТОСУВАННЯ | |
| EP1962601A4 (en) | Fused Amino Coperidines As Diphosphatipetidase 4 Inhibitors For Treating Or Preventing Diabetes | |
| EA201070914A1 (ru) | Применение ранолазина для лечения боли | |
| MX2009013211A (es) | Polipeptidos, dominios variables de anticuerpos y antagonistas. | |
| DE502006004066D1 (de) | Dihydrothienopyrimidine zur behandlung von entzündlichen erkrankungen | |
| CL2008001960A1 (es) | Compuestos derivados de tetrahidropiranocromano, procedimiento de preparacion, composicion farmaceutica, util para inhibir gamma-secretasa, destinados al tratamiento de enfermedades neurodegenetarivas, enfermedad de alzheimer e inhibir el deposito de proteina amiloide. | |
| EA201170624A1 (ru) | Изоникотинамидные антагонисты рецепторов орексинов | |
| TN2010000140A1 (en) | Compositions and methods for use antibodies against sclerostin | |
| EP1793858A4 (en) | HUMAN MONOCLONAL ANTI-CTLA4 ANTIBODIES FOR CANCER TREATMENT | |
| IL193846A (en) | Use of a n-terminal peptide that has been re-regulated to produce a drug to treat inflammatory conditions | |
| MX2009003981A (es) | Agentes moduladores del receptor de calcio. | |
| ATE472998T1 (de) | Kationische liposomale zubereitungen zur behandlung von rheumatoider arthritis | |
| ATE484749T1 (de) | Von anti-trichinella-antikörpern erkannte polypeptide und ihre verwendung | |
| PH12012501743A1 (en) | Antigen binding proteins specific for serum amyloid p component | |
| MA38369A1 (fr) | Peptides et compositions pour le traitement d'une lesion de l'articulation | |
| EP2296665A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF PREMATURE EJACULATION | |
| EP2331130A4 (en) | IGE ANTIBODIES FOR THE TREATMENT OF CANCER | |
| UA114592C2 (uk) | Пептид nd2 та спосіб лікування неврологічного захворювання | |
| FR2868312B1 (fr) | Patch pour le traitement des levres | |
| WO2010116196A3 (en) | Diagnosisof and treatment gluten-induced autoimmune diseases |